Bladder Cancer – Pipeline Review, H1 2017
- Pages: 801
- Published: June 2017
- Report Code: GMDHC9401IDB
Global Markets Direct’s, ‘Bladder Cancer – Pipeline Review, H1 2017’, provides an overview of the Bladder Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Bladder Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape of Bladder Cancer
The report reviews pipeline therapeutics for Bladder Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Bladder Cancer therapeutics and enlists all their major and minor projects
The report assesses Bladder Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Bladder Cancer
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Bladder Cancer
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
4SC AG
Adaptimmune Therapeutics Plc
ADC Therapeutics Sarl
Agenus Inc
Altor BioScience Corp
AndroScience Corp
ANP Technologies Inc
APIM Therapeutics AS
Archivel Farma SL
Argos Therapeutics Inc
Arno Therapeutics Inc
Array BioPharma Inc
Asana BioSciences LLC
Asieris Pharmaceuticals Co Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
AVEO Pharmaceuticals Inc
Bavarian Nordic A/S
Bayer AG
BioCancell Ltd
Biomics Biotechnologies Co Ltd
Bioncotech Therapeutics SL
Biotest AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corp
Cellceutix Corp
Celldex Therapeutics Inc
Celprogen Inc
Celsion Corp
Celyad SA
Cold Genesys Inc
Corvus Pharmaceuticals Inc
CytomX Therapeutics Inc
Cytori Therapeutics Inc
Eisai Co Ltd
Eleven Biotherapeutics Inc
Eli Lilly and Company
Elsalys Biotech SAS
EpiThany Inc
Esperance Pharmaceuticals Inc
Exelixis Inc
Exicure Inc
F. Hoffmann-La Roche Ltd
Five Prime Therapeutics Inc
For-Robin Inc
Gene Signal International SA
Genmab A/S
GlaxoSmithKline Plc
H3 Biomedicine Inc
Hamlet Pharma AB
Hanmi Pharmaceuticals Co Ltd
HitGen LTD
Horizon Pharma Plc
Idera Pharmaceuticals Inc
Immunocore Ltd
Immunomedics Inc
Immupharma Plc
Incanthera Ltd
Incyte Corp
InteRNA Technologies BV
Johnson & Johnson
Laboratoires Pierre Fabre SA
Lion Biotechnologies Inc
LipoMedix Pharmaceutical Inc
MacroGenics Inc
Marina Biotech Inc
MaxiVAX SA
Meabco A/S
Medicenna Therapeutics Corp
MedImmune LLC
Merck & Co Inc
Merck KGaA
Mirati Therapeutics Inc
Moleculin Biotech Inc
MTG Biotherapeutics Inc
NanoCarrier Co Ltd
Nektar Therapeutics
Omeros Corp
Oncogenex Pharmaceuticals Inc
OncoTherapy Science Inc
Oncovir Inc
Optimum Therapeutics LLC
Pfizer Inc
Pharma Mar SA
Philogen SpA
Plexxikon Inc
Polaris Pharmaceuticals Inc
Provecs Medical GmbH
Provectus Biopharmaceuticals Inc
PsiOxus Therapeutics Ltd
Rexahn Pharmaceuticals Inc
Samyang Biopharmaceuticals Corp
Sanofi
Sareum Holdings Plc
Shionogi & Co Ltd
Sierra Oncology Inc
Sillajen Biotherapeutics
Sorrento Therapeutics Inc
Spectrum Pharmaceuticals Inc
Stemline Therapeutics Inc
Sun Pharma Advanced Research Company Ltd
Taiwan Liposome Company Ltd
Taris Biomedical LLC
Theralase Technologies Inc
Theravectys SA
Tolero Pharmaceuticals Inc
Transgene SA
UroGen Pharmaceuticals Ltd
Vakzine Projekt Management GmbH
Vault Pharma Inc
Vaxeal Holding SA
Vaxiion Therapeutics Inc
Viralytics Ltd
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.